A new COVID-19 medication has been approved in Abu Dhabi for the treatment of mild to moderate cases and those who have had direct contact with a patient.
The emirate's Department of Health (DoH) has partnered with Swiss healthcare company Roche to provide casirivimab and imdevimab to certain categories of patients.
The antibody combination has already been approved in the European Union and Japan, and conditionally approved in the UK and Australia.
It is also authorised for emergency use in the United States, India, Switzerland and Canada, and is recommended by the World Health Organisation (WHO).
.@DoHSocial has partnered with Swiss healthcare company @Roche to provide a new Covid-19 medication, approved for emergency use, to treat mild to moderate Covid-19 cases and those who have had direct contact with a positive case.
— مكتب أبوظبي الإعلامي (@ADMediaOffice) December 1, 2021
Read more: https://t.co/vGQXyUvhGB pic.twitter.com/Yj9JxVgemP


UAE allows citizens to travel to Lebanon from Monday
UAE strongly condemns Israeli attacks on Syria
Jumeirah Beach 2 awarded historic Gold Accessibility Certification
Dubai's RTA smart mini-bus service hits 193,000 users
Reckless driver jailed and fined AED70,000 in Abu Dhabi
UAE offers condolences following Saudi helicopter crash
UAE stands in solidarity with Qatar over maritime incident
First genomics-driven UAE clinical trial targets Alzheimer's risk
